{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:37Z","timestamp":1794047497814,"version":"4.8.0"},"reference-count":36,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Novel agents inducing deeper responses have improved the prognosis of patients with multiple myeloma (MM). To assess minimal residual disease (MRD) and stratify patients achieving complete response (CR), advanced technologies such as EuroFlow next-generation flow cytometry (NGF) and next-generation sequencing (NGS) are increasingly utilized. This prospective study evaluated responses in newly diagnosed MM patients undergoing autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy across multiple Japanese medical centers. Patients achieving CR or stringent CR within 100-365 days post-ASCT were included. MRD levels in the bone marrow were assessed using both NGF and NGS (cutoff: 1\u00d710-5) at three time points: 100-365 days, 1 year, and 2 years post-ASCT. A total of 52 patients were analyzed. MRD levels determined by NGF and NGS showed a strong correlation (r=0.9722; P&lt;0.0001). After a median follow-up of 3 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 76.5% (95% confidence interval [CI]: 62.3-85.9%) and 96.2% (95% CI: 85.5-99.0%), respectively. Patients with sustained MRD negativity for &gt;6 months demonstrated superior 3-year PFS compared to those without sustained MRD negativity, as measured by both NGF (100% vs. 67.6%; hazard ratio [HR] =0.06; 95% CI: 0.0005-0.50; P&lt;0.007) and NGS (90.5% vs. 72.2%; HR=0.23; 95% CI: 0.06-0.94; P=0.048). These findings highlighted a strong correlation in the MRD levels assessed by NGF and NGS and validated that sustained MRD negativity was significantly associated with prolonged PFS (clinical trial registered at UMIN 000022238).<\/jats:p>","DOI":"10.3324\/haematol.2025.287411","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:08:21Z","timestamp":1744859301000},"page":"2160-2170","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study"],"prefix":"10.3324","volume":"110","author":[{"given":"Takeshi","family":"Yoroidaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Urushihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Itagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Muta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Fuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.M.","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"78972","doi-asserted-by":"crossref","unstructured":"Palumbo A, Cavallo F, Gay F. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014; 371(10):895-905.","DOI":"10.1056\/NEJMoa1402888"},{"key":"78973","doi-asserted-by":"crossref","unstructured":"Attal M, Lauwers-Cances V, Hulin C. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017; 376(14):1311-1320.","DOI":"10.1056\/NEJMoa1611750"},{"key":"78974","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Kaufman JL, Laubach J. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136(8):936-945.","DOI":"10.1182\/blood.2020005288"},{"key":"78975","doi-asserted-by":"crossref","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017; 31(10):2094-2103.","DOI":"10.1038\/leu.2017.29"},{"key":"78976","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"78977","doi-asserted-by":"crossref","unstructured":"Oliva S, Genuardi E, Paris L. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. eClinicalMedicine. 2023; 60:102016.","DOI":"10.1016\/j.eclinm.2023.102016"},{"key":"78978","doi-asserted-by":"crossref","unstructured":"Medina A, Puig N, Flores-Montero J. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J. 2020; 10(10):108.","DOI":"10.1038\/s41408-020-00377-0"},{"key":"78979","doi-asserted-by":"crossref","unstructured":"De Tute RM, Pawlyn C, Cairns DA. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022; 40(25):2889-2900.","DOI":"10.1200\/JCO.21.02228"},{"key":"78980","doi-asserted-by":"crossref","unstructured":"Diamond B, Korde N, Lesokhin AM. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, singlecentre, phase 2 trial. Lancet Haematol. 2021; 8(6):e422-e432.","DOI":"10.1016\/S2352-3026(21)00130-7"},{"key":"78981","doi-asserted-by":"crossref","unstructured":"Roussel M, Lauwers-Cances V, Robillard N. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My\u00e9lo. J Clin Oncol. 2014; 32(25):2712-2717.","DOI":"10.1200\/JCO.2013.54.8164"},{"key":"78982","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, San-Miguel J, Casneuf T. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021; 39(10):1139-1149.","DOI":"10.1200\/JCO.20.01814"},{"key":"78983","doi-asserted-by":"crossref","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022; 139(4):492-501.","DOI":"10.1182\/blood.2020010439"},{"key":"78984","doi-asserted-by":"crossref","unstructured":"Schmitz A, Brondum RF, Johnsen HE. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02\/HO95 MM trial. BMC Cancer. 2022; 22(1):147.","DOI":"10.1186\/s12885-022-09184-1"},{"key":"78985","doi-asserted-by":"crossref","unstructured":"Rosinol L, Oriol A, Rios R. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023; 142(18):1518-1528.","DOI":"10.1182\/blood.2022019531"},{"key":"78986","doi-asserted-by":"crossref","unstructured":"Costa LJ, Chhabra S, Medvedova E. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022; 40(25):2901-2912.","DOI":"10.1200\/JCO.21.01935"},{"key":"78987","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"78988","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"78989","doi-asserted-by":"crossref","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-2869.","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"78990","doi-asserted-by":"crossref","unstructured":"\u00d3skarsson J\u00de, R\u00f6gnvaldsson S, Thorsteinsdottir S. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: proposal for a bone marrow quality index. Blood Cancer J. 2023; 13(1):177.","DOI":"10.1038\/s41408-023-00951-2"},{"key":"78991","doi-asserted-by":"crossref","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013; 48(3):452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"78992","doi-asserted-by":"crossref","unstructured":"Paiva B, Puig N, Cedena M-T. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020; 38(8):784-792.","DOI":"10.1200\/JCO.19.01231"},{"key":"78993","doi-asserted-by":"crossref","unstructured":"Noori S, Wijnands C, Langerhorst P. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood Cancer J. 2023; 13(1):30.","DOI":"10.1038\/s41408-023-00803-z"},{"key":"78994","doi-asserted-by":"crossref","unstructured":"Notarfranchi L, Zherniakova A, Lasa M. Ultra-sensitive assessment of measurable residual disease (MRD) in peripheral blood (PB) of multiple myeloma (MM) patients using bloodflow. Blood. 2022; 140(Suppl 1):2095-2097.","DOI":"10.1182\/blood-2022-167382"},{"key":"78995","doi-asserted-by":"crossref","unstructured":"Takamatsu H, Takezako N, Zheng J. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Ann Oncol. 2017; 28(10):2503-2510.","DOI":"10.1093\/annonc\/mdx340"},{"key":"78996","doi-asserted-by":"crossref","unstructured":"Martinez-Lopez J, Lahuerta JJ, Pepin F. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014; 123(20):3073-3079.","DOI":"10.1182\/blood-2014-01-550020"},{"key":"78997","doi-asserted-by":"crossref","unstructured":"Lahuerta J-J, Paiva B, Vidriales M-B. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol. 2017; 35(25):2900-2910.","DOI":"10.1200\/JCO.2016.69.2517"},{"key":"78998","doi-asserted-by":"crossref","unstructured":"Perrot A, Lauwers-Cances V, Corre J. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018; 132(23):2456-2464.","DOI":"10.1182\/blood-2018-06-858613"},{"key":"78999","doi-asserted-by":"crossref","unstructured":"Goicoechea I, Puig N, Cedena M-T. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma. Blood. 2021; 137(1):49-60.","DOI":"10.1182\/blood.2020006731"},{"key":"79000","doi-asserted-by":"crossref","unstructured":"Mina R, Musto P, Rota-Scalabrini D. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2023; 24(1):64-76.","DOI":"10.1016\/S1470-2045(22)00693-3"},{"key":"79001","doi-asserted-by":"crossref","unstructured":"Tao Y, Jin S, Yang D. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma. BMC Cancer. 2024; 24(1):406.","DOI":"10.1186\/s12885-024-12077-0"},{"key":"79002","doi-asserted-by":"crossref","unstructured":"Costa LJ, Chhabra S, Medvedova E. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023; 10(11):e890-e901.","DOI":"10.1016\/S2352-3026(23)00236-3"},{"key":"79003","doi-asserted-by":"crossref","unstructured":"Askeland FB, Rasmussen A, Lysen A. Will survival improve by treating multiple myeloma patients at MRD relapse? The Remnant study. Blood. 2023; 142(Suppl 1):4755.","DOI":"10.1182\/blood-2023-189022"},{"key":"79004","doi-asserted-by":"crossref","unstructured":"Attal M, Lauwers-Cances V, Marit G. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1782-1791.","DOI":"10.1056\/NEJMoa1114138"},{"key":"79005","doi-asserted-by":"crossref","unstructured":"Jackson GH, Davies FE, Pawlyn C. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019; 20(1):57-73.","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"79006","doi-asserted-by":"crossref","unstructured":"Richardson PG, Jacobus SJ, Weller EA. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022; 387(2):132-147.","DOI":"10.1056\/NEJMoa2204925"},{"key":"79007","doi-asserted-by":"crossref","unstructured":"Samur MK, Roncador M, Aktas Samur A. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023; 141(14):1724-1736.","DOI":"10.1182\/blood.2022017094"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12033\/78289","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12033\/78744","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12033\/78289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:34Z","timestamp":1794046114000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.287411","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}